A report into the Narcotic Drugs Act (ND Act) has recommended several changes to medical cannabis regulation in Australia.
The report, compiled by Australian National University Professor John McMillan and commissioned by Health Minister Greg Hunt, put forth 26 recommendations aimed at improving the regulatory framework for cultivating, producing and manufacturing medicinal cannabis.
One of the key recommendations is to simplify the current licensing regime of multiple separate cannabis production licences, to a single licence scheme, which would reduce the regulatory burden on both the administration and businesses within in the industry.
The report also questioned if cannabidiol (CBD) should be classed as a drug. According to the World Health Organization, in humans, CBD – the non-psychoactive cannabinoid found in the cannabis plant, “exhibits no effects indicative of any abuse or dependence potential”.
Read the full report here.
ANTG’s James Gaskell joins 2SER Breakfast on 107.3 to discuss his thoughts on ACT’s recent legalisation of cannabis, the conflict of state vs federal laws, and the medicinal cannabis industry in Australia and abroad.
In the first 12 months we expect to see two tonnes plus in export. Exportation will begin to Germany, where we have signed a 10-year supply contract with Cannamedical Pharma.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >